Episode 2 of our monthly GU Cast Journal Club and today we focus on two key papers from recent times - the TRANSLATE trial of transperineal vs transrectal biopsy, and Keynote-564 on the role of adjuvant pembrolizomab following nephrectomy.
After great feedback from last month's launch episode, we are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy

Links to papers and previous podcasts below:
1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial Lancet Oncology 2025
GU Cast on TRANSLATE

2. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma NEJM 2024
GU Cast on K-564 OS paper

GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

We poke around under the hood of a brand new Cyberknife facility here in Melbourne, the first on the East coast of Australia, and find out what it's all about. What is it for, who might benefit, and being surgeons we have to ask, why do they call it a "knife"?! Is it just to make it sound a bit like surgery - stay tuned to find out!
We chat with our good mate Shankar Siva, stereotactic radiation guru, Nigel Middlebrook, Physicist, shows us the back end, Gemma Waters, Radiation Therapist talks us through planning, and Icon Cancer Group Chief Executive Mark Middleton tells us how he decides which expensive projects his team invests in, and how they partnered with Cyberknife experts 5D Clinics for this project.

Even better on our YouTube channel.

This Themed Episode is supported by our Bronze Partner, Icon Cancer Group.

Links:
5D Clinics Melbourne
Icon Cancer Group

Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer.
We are joined today by trial PI Veeru Kasivisvanathan (Urologist, UCL, London), and Francesco Giganti (Radiologist, UCL, London), to discuss the findings and what this means going forward. And it is all good news!

Your host Declan Murphy is on his own today while Renu Eapen on the road in Singapore.

Even better on our YouTube channel

Links below:
JAMA paper published today
Twitter: @compassurology @veerukasi @giga_fra
Website: compassurology.org

Funders:
John Black Charitable Foundation, Prostate Cancer UK, European Association of Urology Research Foundation, Wolfgang.Dieckmann Foundation.